Pharmacologic Substance
Europe Temporarily Halts AstraZeneca’s Vaxzevria COVID-19 Vaccine on Company’s Request
AstraZeneca, Vaxzevria, COVID-19 vaccine, marketing authorization, suspension, Europe, European Medicines Agency (EMA), pharmacovigilance, safety concerns.
FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting
FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.
Zenas Biotech Secures $200 Million for Advancing Obexelimab in Pivotal Immunology Trials
Zenas Biotech, obexelimab, immunology trials, funding, biotechnology, drug development, autoimmune diseases, B-cell-directed therapy.
ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding
ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.
Novo, Gates, and Wellcome Join Forces with $300 Million Initiative to Tackle Global Infectious Diseases
Novo Holdings, Bill & Melinda Gates Foundation, Wellcome Trust, infectious diseases, global health, pandemic preparedness, antimicrobial resistance, research and development, funding, collaboration.
Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer
Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.
Pharmaceutical Industry’s Public Image Deteriorates Post-Pandemic Era
Pharmaceutical industry, reputation, pandemic, public opinion, COVID-19, vaccine development, drug pricing, transparency.
Novartis Invests $1 Billion in Acquisition of Radioligand Therapy Pioneer Mariana
Novartis, Mariana, radioligand therapy, cancer treatment, targeted therapy, precision medicine, billion-dollar acquisition, healthcare innovation.
Ingrezza, a Neurocrine Biosciences Drug, Receives FDA Approval for Tardive Dyskinesia Treatment
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.
FDA Grants Full Approval to Pfizer’s Tivdak for Advanced Cervical Cancer Treatment
FDA, Pfizer, Tivdak, full approval, advanced cervical cancer, treatment, regulatory tracker